GW29-e1374 An EP4 receptor agonist inhibits cardiac fibrosis through activation of PKA signaling in hypertrophied heart
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2018.08.156
Abstract: Cardiac fibrosis is a pathological feature of myocardium of failing heart and plays causative roles in arrhythmia and cardiac dysfunction, but its regulatory mechanisms remain largely elusive. In this study, we investigated the effects of… read more here.
Keywords: heart; fibrosis; receptor agonist; cardiac fibrosis ... See more keywords
OWE-015 Prostaglandin E2 mediates innate immune suppression in acute-on-chronic liver failure via the EP4 receptor
Sign Up to like & getrecommendations! Published in 2018 at "Gut"
DOI: 10.1136/gutjnl-2018-bsgabstracts.208
Abstract: Introduction Bacterial infection is a major cause of hospital admission in liver cirrhosis and patients are highly prone to nosocomial infection. Innate immune dysfunction is strongly implicated in these patients. We showed prostaglandin E2 (PGE2)… read more here.
Keywords: aclf patients; pge2; dysfunction; ep4 receptor ... See more keywords
Abstract 2330: Discovery of EP4 receptor antagonist KF-0210 for the treatment of cancers
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2330
Abstract: Background: It is known that tumors with more infiltrated immune cells have better responses to PD-1/PD-L1 antibody therapy. PGE2 is involved in the regulation of the cancer microenvironment and tumor growth, mainly through the EP4… read more here.
Keywords: tumor growth; ep4 receptor; treatment; tumor ... See more keywords
The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23031599
Abstract: Anti-CD20 monoclonal antibodies (MAbs) have revolutionized the treatment of B-cell leukemia and lymphoma. However, many patients do not respond to such treatment due to either deficiency of the complementary immune response or resistance to apoptosis.… read more here.
Keywords: leukemia lymphoma; cell leukemia; ep4 receptor; monoclonal antibodies ... See more keywords